Latest Insider Transactions at International Flavors & Fragrances Inc (IFF)
This section provides a real-time view of insider transactions for International Flavors & Fragrances Inc (IFF). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INTERNATIONAL FLAVORS & FRAGRANCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INTERNATIONAL FLAVORS & FRAGRANCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2022
|
De Villeplee Christophe Fauchon President, Scent |
SELL
Open market or private sale
|
Direct |
629
-7.14%
|
$83,028
$132.59 P/Share
|
|
May 05
2022
|
Edward D Breen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,089
+41.36%
|
-
|
|
May 05
2022
|
Barry A. Bruno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
289
+50.0%
|
-
|
|
May 05
2022
|
Christina A Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,089
+12.08%
|
-
|
|
May 05
2022
|
Ilene S Gordon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,089
+31.72%
|
-
|
|
May 05
2022
|
Matthias Heinzel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,089
+44.76%
|
-
|
|
May 05
2022
|
Kare Schultz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,089
+44.76%
|
-
|
|
May 02
2022
|
De Villeplee Christophe Fauchon President, Scent |
SELL
Open market or private sale
|
Direct |
630
-6.67%
|
$76,230
$121.68 P/Share
|
|
Apr 01
2022
|
Francisco Fortanet EVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,912
-6.56%
|
$256,208
$134.33 P/Share
|
|
Apr 01
2022
|
Francisco Fortanet EVP, Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
5,006
+14.66%
|
-
|
|
Apr 01
2022
|
Robert G. Anderson Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
625
-3.6%
|
$83,750
$134.33 P/Share
|
|
Apr 01
2022
|
Robert G. Anderson Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,741
+9.11%
|
-
|
|
Apr 01
2022
|
Nicolas Mirzayantz President, Nourish |
SELL
Payment of exercise price or tax liability
|
Direct |
2,042
-5.08%
|
$273,628
$134.33 P/Share
|
|
Apr 01
2022
|
Nicolas Mirzayantz President, Nourish |
BUY
Exercise of conversion of derivative security
|
Direct |
4,353
+9.78%
|
-
|
|
Apr 01
2022
|
De Villeplee Christophe Fauchon President, Scent |
SELL
Sale (or disposition) back to the issuer
|
Direct |
256
-2.64%
|
$34,304
$134.33 P/Share
|
|
Apr 01
2022
|
De Villeplee Christophe Fauchon President, Scent |
BUY
Exercise of conversion of derivative security
|
Direct |
2,461
+10.82%
|
$145,199
$59.05 P/Share
|
|
Mar 15
2022
|
Robert G. Anderson Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
288
-1.81%
|
$34,560
$120.48 P/Share
|
|
Mar 15
2022
|
Robert G. Anderson Controller |
BUY
Grant, award, or other acquisition
|
Direct |
662
+4.0%
|
-
|
|
Feb 19
2022
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
188
-3.76%
|
$25,380
$135.03 P/Share
|
|
Feb 19
2022
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
585
+10.47%
|
-
|
|
Feb 19
2022
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-7.56%
|
$36,855
$135.03 P/Share
|
|
Feb 19
2022
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
708
+16.39%
|
-
|
|
Feb 19
2022
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
155
-3.11%
|
$20,925
$135.03 P/Share
|
|
Feb 19
2022
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
616
+11.01%
|
-
|
|
Feb 14
2022
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
152
-4.98%
|
$20,064
$132.1 P/Share
|
|
Feb 14
2022
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
366
+10.7%
|
-
|
|
Feb 14
2022
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
132
-2.94%
|
$17,424
$132.1 P/Share
|
|
Feb 14
2022
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
525
+10.46%
|
-
|
|
Feb 14
2022
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
120
-2.64%
|
$15,840
$132.1 P/Share
|
|
Feb 14
2022
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
366
+7.46%
|
-
|
|
Jan 02
2022
|
De Villeplee Christophe Fauchon President, Scent |
BUY
Exercise of conversion of derivative security
|
Direct |
784
+9.78%
|
$116,816
$149.12 P/Share
|
|
Dec 31
2021
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
891
-18.36%
|
$132,759
$149.82 P/Share
|
|
Dec 31
2021
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
3,241
+40.05%
|
-
|
|
Dec 31
2021
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,236
-31.49%
|
$184,164
$149.82 P/Share
|
|
Dec 31
2021
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,241
+45.23%
|
-
|
|
Dec 30
2021
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
3,481
+45.49%
|
$400,315
$115.48 P/Share
|
|
Sep 15
2021
|
Winder Investment Pte LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
979,000
+3.75%
|
$139,997,000
$143.75 P/Share
|
|
May 14
2021
|
Ilene S Gordon Director |
BUY
Open market or private purchase
|
Direct |
1,000
+44.35%
|
$140,000
$140.39 P/Share
|
|
May 13
2021
|
Simon Herriott Pres. Health & Bioscience |
SELL
Open market or private sale
|
Direct |
1,332
-46.8%
|
$183,816
$138.47 P/Share
|
|
May 13
2021
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
1,513
+34.71%
|
$173,995
$115.48 P/Share
|
|
May 06
2021
|
Carol Anthony Davidson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
255
+50.0%
|
-
|
|
May 06
2021
|
Ilene S Gordon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
255
+50.0%
|
-
|
|
May 06
2021
|
Kathryn Jean Boor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
255
+50.0%
|
-
|
|
May 06
2021
|
Matthias Heinzel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
255
+50.0%
|
-
|
|
May 06
2021
|
Edward D Breen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
255
+35.92%
|
-
|
|
May 06
2021
|
Kare Schultz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
255
+50.0%
|
-
|
|
May 06
2021
|
Christina A Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,047
+13.28%
|
-
|
|
May 05
2021
|
Rustom Jilla CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,198
+27.67%
|
$316,512
$144.67 P/Share
|
|
Apr 05
2021
|
Gonzalez Susana Suarez EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,176
-7.21%
|
$163,464
$139.0 P/Share
|
|
Apr 05
2021
|
Robert G. Anderson Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-3.68%
|
$80,898
$139.0 P/Share
|